Current Approaches in NSCLC Targeting K-RAS and EGFR.
Ontology highlight
ABSTRACT: The research and treatment of non-small cell lung cancer (NSCLC) have achieved some important advances in recent years. Nonetheless, the overall survival rates for NSCLC remain low, indicating the importance to effectively develop new therapies and improve current approaches. The understanding of the function of different biomarkers involved in NSCLC progression, survival and response to therapy are important for the development of early detection tools and treatment options. Epidermal growth factor receptor (EGFR) and Kirsten rat sarcoma viral oncogene homolog (K-RAS) are two of the main significant biomarkers for the management of NSCLC. Mutations in these genes were associated with development and response to therapies. For example, the use of small molecule tyrosine kinase (TK) inhibit
SUBMITTER: Aran V
PROVIDER: S-EPMC6888213 | biostudies-literature | 2019 Nov
REPOSITORIES: biostudies-literature
ACCESS DATA